Hospital De La Santa Creu I Sant Pau

The Hospital De La Santa Creu I Sant Pau conducts cutting‑edge research on neoplasms, focusing on solid tumors and hematologic malignancies across the Barcelona region.

• Advanced colorectal cancer with BRAF V600E mutation
• Early ER+/HER2‑ negative breast cancer
• Metastatic squamous non‑small cell lung cancer
• Relapsed or refractory diffuse large B‑cell lymphoma

A total of 13 clinical trials involve 186 investigators, advancing therapeutic options for cancer patients.

Within the department of Neurology, the site explores treatments for neurodegenerative and headache disorders, aiming to improve quality of life for affected individuals.

• Gene‑silencing therapy for Huntington’s disease
• Pediatric acute migraine management with novel agents
• Long‑term safety assessments in chronic neurological conditions

Ongoing studies leverage the expertise of 186 investigators to evaluate efficacy and safety in the nervous system field.

Research in immune system diseases targets autoimmune skin conditions, employing innovative immunomodulatory approaches to reduce disease burden.

• Subacute and chronic cutaneous lupus erythematosus
• Severe alopecia areata in adults and adolescents
• Evaluation of novel biologics for refractory autoimmune disease

The department’s 13 trials aim to expand therapeutic options for patients with challenging immune‑mediated disorders.

The site’s work on respiratory tract diseases integrates oncology and pulmonary health, seeking to improve outcomes for lung‑related malignancies.

• Immunotherapy comparison in metastatic squamous non‑small cell lung cancer
• Respiratory physiological monitoring within cancer trials

Clinical investigations combine oncology expertise with respiratory assessments to refine treatment strategies.

Studies in digestive system diseases concentrate on colorectal cancer, exploring targeted regimens that enable curative surgical interventions.

• Induction therapy for BRAF‑mutated advanced colorectal cancer
• Surgical feasibility after neoadjuvant targeted treatment

These trials contribute to multidisciplinary care pathways for patients with gastrointestinal malignancies.

The department supports investigations into congenital and hereditary conditions, emphasizing early detection and genetic counseling to guide preventive strategies.

• Genetic screening for hereditary cancer predisposition
• Neonatal neurological assessments linked to long‑term outcomes

Collaborative efforts with genetics specialists aim to integrate precision medicine from birth onward.

Research on circulatory and respiratory physiological phenomena underpins many therapeutic trials, providing biomarkers that inform treatment response.

• Circulatory biomarker analysis in oncology studies
• Respiratory function evaluation during lung cancer therapy

These physiological insights enhance the safety and effectiveness of interventions across multiple disease areas.